Experts provide an overview of CAR T-cell therapy for lymphoma and side effects. This webinar is designed for those with cancer, their caregivers, and their families.
Topics Discussed
00:00 - Welcome and Introductions
01:55 - Background on CAR T in lymphoma
02:57 - CAR T efficacy in lymphoma
07:01 - CAR T toxicity in lymphoma
07:49 - Cytokine release syndrome (CRS)
12:37 - ICANS (neurotoxicity)
15:13 - Bone marrow suppression
16:10 - Non-relapse mortality (NRM)
18:30 - CAR T care team and process
20:41 - Leukapheresis
22:12 - Manufacturing and bridging therapy
23:37 - Lymphodepletion chemotherapy
25:09 - Infusion of the CAR T-cells and infusion settings
28:29 - Caregiver role
30:12 - Key education points
33:32 - Real-life considerations for patients and caregivers
41:16 - Free resources available
42:31 - Support services and financial and education resources
Question & Answer Session
44:49 - How long do the infused CAR T-cells last in the body?
45:51 - If you have been diagnosed with hypogammaglobulinemia, would that make CAR T more difficult?
46:23 - Under what conditions is performing autologous CAR T not feasible?
46:57 - Is there a relationship between low skeletal muscle mass and overall survival for CAR T?
48:03 - If a patient had previously harvested stem cells, could T-cells be collected from these?
48:34 - Does LLS have peer-support for CAR T specifically and people who have gone through CAR-T?
49:42 - How is the decision made regarding the site of care -- in-patient versus out-patient -- for CAR T infusion?
50:36 - What are the long-term side effects of CAR T?
51:57 - Can patients with impaired renal function undergo CAR T?
53:06 - Is there an association with acquiring autoimmune disease after CAR T?
53:33 - What is the age of the oldest patients you have treated with CAR T and is age any sort of predictor for response?
54:56 - During the 30 days of caregiver monitoring doe the caregiver need to be present at all times, or can a patient be left unsupervised for brief periods to run an errand, etc.?
56:09 - Is there any research being done about expanding the indication of CAR T, such as for solid tumors?
57:06 - Is there eligibility for CAR T for those who don't have insurance?
58:22 - Does triple-hit lymphoma effect the results of CAR T treatment and survival rates?
59:25 - Have you run into situations where CAR T is not authorized by insurance and how are those cases managed?
1:00:07 - If you are in partial remission are you eligible for CAR T?
1:00:21 - Drug approvals and interactions with CAR T
1:01:38 - Conclusion
The Patient Webinar on CAR T-Cell Therapy for Lymphoma and Side Effects occurred in May 2023. This informational program was created in conjunction with the recently updated NCCN Guidelines for Patients® for Immunotherapy Side Effects: CAR T-Cell Therapy. Access the free patient guidelines: [ Ссылка ]
The NCCN Guidelines for Patients are available to read and download for free online and via the NCCN Patient Guides for Cancer mobile app. Printed editions can be ordered from Amazon.com for a small fee.
NCCN Guidelines for Patients DO NOT replace the expertise and clinical judgment of the clinician.
Supporters:
This webinar is supported through the NCCN Foundation and by contributions from our corporate supporters: Bristol Myers Squibb; and Kite, a Gilead Company.
__________________________________________________________
About NCCN Foundation®:
NCCN FOUNDATION® is a 501(c)3 organization founded by the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education—to empower people living with cancer and advance oncology innovation. For more information or to make a donation, visit [ Ссылка ]
__________________________________________________________
About NCCN:
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit [ Ссылка ] for more information.
Subscribe to our channel for the latest in cancer care: [ Ссылка ]...
Connect with us!
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
